ResearcherConsejo Superior de Investigaciones CientíficasActive in the last 2 years
Núria Vázquez-Bellón
Matched on ORCID iD 0000-0002-0255-2875; OpenAlex author ID A5106423299. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2024: 1 paper · 2025: none · 2026: 2 papers
Papers 3
- Lateral flow immunoassay detection of soluble AXL for pancreatic ductal adenocarcinoma diagnosis. Co-author DOI 10.1016/j.talanta.2026.129973↗
- PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. Co-author DOI 10.1126/sciadv.adu8849↗
- Hallmarks of pancreatic cancer: spotlight on TAM receptors. Co-author DOI 10.1016/j.ebiom.2024.105278↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Neus Martínez‐Bosch · 3 shared papers, 2024–2026 · strength 0.84
- Paper Hallmarks of pancreatic cancer: spotlight on TAM receptors. DOI 10.1016/j.ebiom.2024.105278↗
- Paper Lateral flow immunoassay detection of soluble AXL for pancreatic ductal adenocarcinoma diagnosis. DOI 10.1016/j.talanta.2026.129973↗
- Paper PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. DOI 10.1126/sciadv.adu8849↗
- Pilar Navarro · 3 shared papers, 2024–2026 · strength 0.84
- Paper Hallmarks of pancreatic cancer: spotlight on TAM receptors. DOI 10.1016/j.ebiom.2024.105278↗
- Paper Lateral flow immunoassay detection of soluble AXL for pancreatic ductal adenocarcinoma diagnosis. DOI 10.1016/j.talanta.2026.129973↗
- Paper PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. DOI 10.1126/sciadv.adu8849↗
- Pablo Garcı́a de Frutos · 2 shared papers, 2024–2026 · strength 0.61
- Laura Visa · 1 shared paper, 2026 · strength 0.30
- J.‐Pablo Salvador · 1 shared paper, 2026 · strength 0.30
- Noemí Manero‐Rupérez · 1 shared paper, 2026 · strength 0.23
- Carmen E. Guerra · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.